Leprosy Treatment - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The leprosy treatment market is expected to increase from USD 0.78 billion in 2025 to USD 0.82 billion in 2026 and reach USD 1.08 billion by 2031, growing at a CAGR of 5.74% over 2026-2031. This report is segmented by Therapy Type (Multi-Drug Therapy, Antibiotics, Immunotherapy, and More), Disease Type (Paucibacillary Leprosy, Multibacillary Leprosy), Distribution Channel (Hospital Pharmacies, and More), End-User (Hospitals and Specialty Clinics, and More), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, South America). Market Forecasts are Provided in Value (USD).

Global Leprosy Treatment Market Trends and Insights

Rising Multidrug Therapy Adoption Through National NTD Programs

The WHO-endorsed MDT regimen remains the foundation of the leprosy treatment market because it has delivered treatment success above 95% in non-resistant cases and remains the accepted standard across endemic national programs. India expanded this treatment base further when its health ministry moved paucibacillary care from a 2-drug approach to a 3-drug combination from April 2025. Single-dose rifampicin reached 1.7 million people in 37 countries during 2024, and that volume is likely to keep rising as contact examination coverage moves toward the WHO target of 90% from a 59% base. This means the leprosy treatment market is being lifted less by price expansion and more by protocol widening, better case classification, and the addition of funded prophylaxis. It also means generic manufacturers can capture added volume through public procurement even when first-line therapy itself remains donation-linked.

Expanding Active Case Detection and Contact Tracing

Active case detection is one of the strongest volume drivers in the leprosy treatment market because reported case counts still trail the likely underlying disease burden in several endemic regions. Brazil, India, and Indonesia accounted for nearly 80% of new global cases in 2024, yet contact examination coverage remained at 59%, which leaves a large pool of cases still outside treatment channels. India is using the Nikusth 2.0 platform for district-level reporting, and Nepal’s Global Leprosy Mapping Project recorded 11,844 cases across 237 municipalities in 31 districts between January and June 2025.Digital mapping tools and GIS-based monitoring are making case finding more targeted, and the WHO-endorsed Leprosy Elimination Monitoring Tool is helping standardize burden review across endemic districts. Each newly identified patient starts a treatment cycle and adds directly to procurement demand, which makes early detection one of the clearest demand links in the leprosy treatment market.

Delayed Diagnosis and Late Treatment Initiation

Late diagnosis remains a basic drag on the leprosy treatment market because M. leprae often has an incubation period of 5 to 7 years, and there is still no rapid, low-cost point-of-care test that can be deployed widely. In 2024, 9,157 new patients were reported with Grade 2 disabilities, which means treatment came too late to prevent permanent nerve damage in many cases. A 14-question machine learning-based Leprosy Suspicion Questionnaire published in 2025 offers a practical community screening tool that does not depend on a full clinical examination. The problem is that adoption of such tools into national field programs still takes time, especially across large rural systems. Until diagnosis improves, the leprosy treatment market will continue to face understated procurement signals and recurring stock planning gaps in endemic districts.

Other drivers and restraints analyzed in the detailed report include:

• Improved Access to Fixed-Dose and Paucibacillary Treatment Protocols
• Growing Donor Support for Neglected Tropical Disease Elimination
• Stigma and Care-Seeking Suppression

Segment Analysis

Multi-Drug Therapy held 41.83% leprosy treatment market share in 2025, which shows how deeply national protocols still center on the standard WHO regimen. That position came from long-standing program standardization rather than normal brand competition, because endemic countries continue to receive MDT through the WHO-Novartis donation structure. The donation model also limits price-based differentiation for generic suppliers, since first-line access is defined more by eligibility and supply continuity than by commercial promotion. The 2026-2030 arrangement that also funds single-dose rifampicin for post-exposure prophylaxis means the leprosy treatment market is still adding scope around MDT rather than moving away from it.

Antibiotics are projected to grow at 6.26% CAGR through 2031, making this the fastest-moving therapy line within the leprosy treatment market. The shift is being shaped by experimental regimens that aim to shorten treatment and respond better to resistance concerns than current first-line protocols. Lupin’s January 2026 collaboration with TB Alliance on telacebec also brought a first-in-class asset into the leprosy treatment market, with the possibility of premium pricing in drug-resistant settings if approval is secured.

Paucibacillary leprosy accounted for a 54.67% share of the leprosy treatment market size in 2025, which kept it as the larger disease group by patient volume. Multibacillary leprosy is expected to grow faster at a 6.54% CAGR through 2031 because active case finding is uncovering more patients who were previously missed, delayed, or misclassified. The revenue weight of multibacillary disease is higher because each patient usually requires a 12-month MDT course, while paucibacillary treatment generally runs for 6 months. That creates a stronger drug volume effect in the faster-growing disease segment across the leprosy treatment market.

Clinical pressure is also stronger in multibacillary care because this group drives most Type 1 and Type 2 reaction burden and therefore needs added spending on corticosteroids, thalidomide, and wound care. Brazil’s June 2025 RIMOXCLAMIN data also reported a 17.9% improvement in foot sensitivity against standard WHO-MDT, which matters most in patients with higher nerve damage risk. WHO also reported 289 new child Grade 2 disability cases in 2024, with 40% of them in the African Region, which shows that pediatric multibacillary management still remains under-addressed in the leprosy treatment market.

Complete Report Scope:

• By Therapy Type
  • Multi-Drug Therapy
  • Antibiotics
  • Immunotherapy
  • Other Treatment Types
• By Disease Type
  • Paucibacillary Leprosy
  • Multibacillary Leprosy
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By End-User
  • Hospitals and Specialty Clinics
  • Primary Healthcare Centers
  • Community Health Programs
  • Other End-Users
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America held 42.47% leprosy treatment market share in 2025, even though the region accounted for very few cases compared with endemic parts of Asia, Africa, and Latin America. The United States reports only 150 to 250 autochthonous and imported cases a year, but per-patient spending is much higher because of specialist physician billing, insurance reimbursement, diagnostic workup costs, and regulated thalidomide use for ENL through the REMS system. Canada mainly manages imported cases through infectious disease and travel medicine services, while Mexico combines pockets of endemic disease with urban healthcare systems that have higher treatment economics. Fiocruz received authorization from Anvisa in October 2024 to lead the Phase 1b vaccine study in Brazil, which links North American research progress to South American field development.

Asia-Pacific is projected to grow at a 7.43% CAGR through 2031, making it the fastest-growing regional block in the leprosy treatment market. India contributes around 50% of global new cases, and its National Strategic Plan and Roadmap for Leprosy 2023-2027 is pushing faster case finding, contact tracing, SDR rollout, and primary care decentralization. China, Indonesia, and the Philippines add meaningful regional volume, while Nepal’s mapping program showed how many cases can still be identified when surveillance is expanded across remote districts. Australia and South Korea matter less by case count but remain useful as research and digital health nodes for the leprosy treatment market as AI-supported screening tools move toward wider evaluation.

Europe remained a small but high-value part of the leprosy treatment market, with 79 new cases in 2024, including 14 locally acquired cases concentrated in Türkiye, Uzbekistan, Ukraine, France, and Portugal. Germany, France, and the United Kingdom retain specialist treatment capacity for imported cases, which supports higher spending per patient than in donor-funded endemic settings. In the Middle East and Africa, South Africa manages rural endemic burden while GCC countries mostly see cases in expatriate worker populations, and Nigeria’s recent supply crisis showed how fragile last-mile delivery can remain in sub-Saharan Africa. South America is anchored by Brazil, where heavy disease burden sits alongside major clinical work such as the RIMOXCLAMIN submission and the Fiocruz LepVax study, giving the region a larger future role in the leprosy treatment market than its current revenue weight suggests.

List of Companies Covered in this Report:

• Alkem Laboratories Ltd.
• Aurobindo Pharma
• Bristol-Myers Squibb
• Cadila Pharmaceuticals Ltd.
• Cipla
• Dr. Reddy’s Laboratories
• Glenmark Pharmaceuticals
• Hetero Labs Limited
• Lupin
• Macleods Pharmaceuticals Ltd.
• Mankind Pharma Ltd.
• Novartis
• Pfizer
• Sandoz Group AG
• Sanofi
• Sun Pharmaceuticals Industries
• Teva Pharmaceutical Industries
• Torrent Pharmaceuticals
• Viatris
• Zydus Lifesciences Ltd.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support